Overview

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

Status:
Not yet recruiting
Trial end date:
2031-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized, histology-agnostic trial. Although there will be a case mix of histologies, we now know that individual histologies are composed of a heterogeneous mix of molecular alterations. It is not clear whether one case mix is better or worse than another. Thus, we are testing a strategy of molecular matching that may apply across different cancers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin